I am a
Home I AM A Search Login

Papers of the Week

Papers: 8 Jan 2022 - 14 Jan 2022

Animal Studies, Pharmacology/Drug Development

2020 Nov 16

ACS Appl Bio Mater



Evaluation of Injectable Naloxone-Releasing Hydrogels.


Crowe KM, Siddiqui Z, Harbour V, Kim KK, Syed S, Paul R, Roy A, Naik R, Mitchell K, Mahajan A, Sarkar B, Kumar VA
ACS Appl Bio Mater. 2020 Nov 16; 3(11):7858-7864.
PMID: 35019526.


The opioid epidemic in the United States is a serious public health crisis affecting over 1.7 million Americans. In the last two decades, almost 450 000 people have died from an opioid overdose, with nearly 20% of these deaths occurring in 2017 and 2018 alone. During an overdose, overstimulation of the μ-opioid receptor leads to severe and potentially fatal respiratory depression. Naloxone is a competitive μ-opioid-receptor antagonist that is widely used to displace opioids and rescue from an overdose. Here, we describe the development of a slow-release, subcutaneous naloxone formulation for potential management of opioid overdose, chronic pain, and opioid-induced constipation. Naloxone is loaded into self-assembling peptide hydrogels for controlled drug release. The mechanical, chemical, and structural properties of the nanofibrous hydrogel enable subcutaneous administration and slow, diffusion-based release kinetics of naloxone over 30 days in vitro. The naloxone hydrogel scaffold showed cytocompatibility and did not alter the β-sheet secondary structure or thixotropic properties characteristic of self-assembling peptide hydrogels. Our results show that this biocompatible and injectable self-assembling peptide hydrogel may be useful as a vehicle for tunable, sustained release of therapeutic naloxone. This therapy may be particularly suited for preventing renarcotization in patients who refuse additional medical assistance following an overdose.